Colorectal Cancer Market Size to Reach USD 17.9 Billion by 2035, Impelled by Advancements in Early Diagnosis & Screening

February 28, 2025 | Healthcare

VIEW FULL TABLE OF CONTENTS

Colorectal Cancer Market Outlook 2025-2035:

The Colorectal cancer market reached a value of USD 13.9 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 17.9 Billion by 2035, exhibiting a growth rate (CAGR) of 2.34% during 2025-2035. The colorectal cancer (CRC) treatment market is undergoing a dynamic transformation, driven by advancements in diagnostics and therapeutic innovations. Early and accurate diagnosis is becoming increasingly vital, leveraging liquid biopsy, next-generation sequencing (NGS), AI-powered imaging, and biomarker-based screening tests. These cutting-edge technologies enable healthcare professionals to detect CRC at earlier stages, differentiate between genetic subtypes, and personalize treatment approaches, ultimately improving patient survival rates. Simultaneously, the therapeutic landscape is evolving with the introduction of targeted therapies, immunotherapies, and novel drug combinations. While traditional treatments such as surgery, chemotherapy, and radiation therapy remain essential, immune checkpoint inhibitors, monoclonal antibodies, and tumor microenvironment-targeting agents are revolutionizing disease management with enhanced efficacy and fewer side effects. Additionally, combination therapies, including immunotherapy with chemotherapy or targeted agents, are improving treatment response rates and long-term disease control. These advancements are reshaping colorectal cancer care, offering new hope for patients and improving overall treatment outcomes worldwide.

Colorectal Cancer Market Outlook

To get more information on this market, Request Sample

Expansion of Targeted & Immunotherapies in Colorectal Cancer Treatment

The colorectal cancer treatment landscape is witnessing significant advancements with the increased development and approval of targeted therapies and immunotherapies. Immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4 inhibitors, are improving survival outcomes, particularly in microsatellite instability-high (MSI-H) and mismatch repair-deficient (dMMR) CRC patients. Monoclonal antibodies targeting EGFR (e.g., Cetuximab, Panitumumab) and VEGF (e.g., Bevacizumab) are enhancing precision treatment by inhibiting tumor growth and angiogenesis. The rise of personalized medicine, driven by biomarker-based patient selection, is optimizing therapy effectiveness while minimizing side effects. Combination strategies, such as immunotherapy with chemotherapy or targeted agents, are further enhancing treatment response rates. Ongoing clinical trials continue to explore novel agents and next-generation immune-based approaches, offering hope for improved disease control and long-term survival.

Rising Investments in Oncology R&D Driving Colorectal Cancer Advancements

The colorectal cancer (CRC) market is benefiting from significant investments in oncology research and development (R&D), leading to breakthrough innovations in treatment strategies. Increased funding is accelerating the discovery of novel drug candidates, including next-generation immunotherapies, targeted therapies, and tumor microenvironment modulators. Combination therapies, such as immune checkpoint inhibitors with chemotherapy or targeted agents, are being extensively studied to enhance treatment efficacy. Precision medicine approaches, leveraging biomarkers and genetic profiling, are improving patient selection for tailored therapies, reducing side effects and increasing survival rates. Public and private sector investments are supporting large-scale clinical trials to bring promising therapies to market faster. Collaborations between pharmaceutical companies, biotech firms, and academic institutions are driving drug innovation and regulatory approvals. These investments are reshaping colorectal cancer treatment, offering new hope for patients with advanced or treatment-resistant disease.

Marketed Therapies in the Colorectal Cancer Market

Vectibix (Panitumumab) – Amgen

Vectibix (Panitumumab) is a monoclonal antibody used in the treatment of metastatic colorectal cancer (mCRC). It specifically targets the epidermal growth factor receptor (EGFR) to inhibit cancer cell growth in RAS wild-type CRC patients.

Avastin (Bevacizumab) - Roche

Avastin (Bevacizumab) – Genentech/Roche is an anti-VEGF monoclonal antibody used in the treatment of metastatic colorectal cancer (mCRC). It works by inhibiting vascular endothelial growth factor (VEGF), preventing tumor angiogenesis and restricting blood supply to cancer cells.

Stivarga (Regorafenib) - Bayer Healthcare

Stivarga (Regorafenib) is an oral multi-kinase inhibitor approved for the treatment of metastatic colorectal cancer (mCRC) in patients who have progressed after standard therapies. It targets multiple pathways, including angiogenesis, oncogenesis, and tumor microenvironment regulation, to slow cancer progression.

Erbitux (Cetuximab) - Eli Lilly and Company

Erbitux (Cetuximab) – Eli Lilly and Company is a monoclonal antibody used for the treatment of metastatic colorectal cancer (mCRC) in RAS wild-type patients. It specifically targets the epidermal growth factor receptor (EGFR) to inhibit tumor growth and enhance the effects of chemotherapy.

Emerging Therapies in the Colorectal Cancer Market

XL 092 – Exelixis

Exelixis is advancing (XL092), an investigational tyrosine kinase inhibitor, in combination with atezolizumab for the treatment of metastatic colorectal cancer (mCRC). The STELLAR-303 Phase 3 trial is evaluating this combination against regorafenib in patients with microsatellite stable or low microsatellite instability mCRC who have progressed after standard therapies. This study aims to address the limited treatment options and poor prognosis associated with advanced mCRC.

Drug Name	Company Name	MOA	ROA
XL 092	Exelixis	Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-mer inhibitors; Proto-oncogene protein c-met inhibitors; Vascular endothelial growth factor receptor antagonists	Oral

Detailed list of emerging therapies for Colorectal Cancer provided in the final report…

Leading Companies in the Colorectal Cancer Market:

The colorectal cancer (CRC) treatment market is undergoing a significant transformation, driven by competition and breakthrough innovations from leading pharmaceutical and biotech companies. Key players such as Amgen, Roche, Bayer Healthcare, Eli Lilly, and Exelixis are heavily investing in targeted therapies, immunotherapies, and combination treatments to improve CRC management. A major shift is occurring, moving beyond traditional chemotherapy and radiation therapy toward precision medicine approaches that specifically target tumor growth, angiogenesis, and immune evasion mechanisms. This is evident in the development of novel therapies such as Vectibix (Panitumumab), Avastin (Bevacizumab), Stivarga (Regorafenib), and Erbitux (Cetuximab), which aim to enhance treatment efficacy, reduce side effects, and improve survival outcomes. Supported by ongoing clinical trials, biomarker-driven therapies, and regulatory advancements, the CRC treatment landscape is evolving toward personalized and more effective treatments, offering new hope for patients and better long-term disease management.

Key Players in the Colorectal Cancer Market:

The key players in the Colorectal Cancer market who are in different phases of developing different therapies are Amgen, Roche, Bayer Healthcare, Eli Lilly, Exelixis, and others.

Key Players in the Colorectal Cancer Market

Regional Analysis:

The colorectal cancer (CRC) treatment market is heavily concentrated in developed regions such as the United States, Germany, the UK, France, Italy, Spain, and Japan, where advancements in oncology research and precision medicine are driving innovation. The United States plays a pivotal role in this market due to its leadership in pharmaceutical R&D, biomarker-driven therapies, and immuno-oncology advancements. While current treatment approaches focus on chemotherapy, radiation therapy, and surgical interventions, significant progress is being made in understanding the molecular and genetic landscape of CRC, leading to the development of targeted therapies and immunotherapies. The market is also being fueled by increased investments in oncology research, accelerated regulatory approvals for novel treatments, and strategic collaborations between pharmaceutical companies, academic institutions, and healthcare providers. These efforts are expanding treatment options, improving disease management, and ultimately enhancing survival outcomes and quality of life for patients affected by colorectal cancer.

Key information covered in the report

Base Year: 2024
Historical Period: 2019-2024
Market Forecast: 2025-2035

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the colorectal cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the colorectal cancer market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current colorectal cancer-marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Colorectal Cancer Market Size to Reach USD 17.9 Billion by 2035, Impelled by Advancements in Early Diagnosis & Screening

Purchase Options Discount
Offer

Inquire Before Buying

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.